To launch wound care products
US-based biopharmaceutical company Oculus Innovative Sciences, Inc has tied up with India’s Genetix Biotech to expand its footprints in the country. As per the agreement, Genetix, which deals in distribution of biotechnology, life sciences, laboratory research products would be the exclusive distributor of Oculus’s family of products based upon the Microcyn technology platform such as Microdacyn60, Microcyn Skin and Wound HydroGel in India.
Oculus’s Microcyn technology based product are intended for the management of exudating wounds such as leg ulcers, pressure ulcers, diabetic ulcers, first- and second-degree burns, and mechanically or surgically debrided wounds.
“The product was initially launched in the US market, however, with growing demand, the company is looking to expand in emerging markets such as India,” says Bruce Thornton, Executive Vice President, Oculus Innovative Sciences.
He also claimed that Oculus’s products, which are sold throughout the US and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. Oculus started expanding in 2007 and currently its products are available in more than 30 countries. Company has over 40 patents and 10FDA approval in 10 CE mark.
Genetix, which has pan India footprints in the distribution of pharma products, is likely to give a bigger push to the product in India. Arun Prakash, Chief Executive Officer, Genetix Biotech said that Genetix will create awareness about the products among health practitioners.
He further said that Genetix will introduce the products to hospitals and chemist shops across India. “Usually, hospitals have plastic surgeon and dermatologist, they could use it for burns, diabetic ulcers, surgically debrided wounds,” adds Prakash.
The product – Microdacyn60,which has been launched in India is a Microcyn-based family of products, generated through a unique, patented electrochemical treatment of dilute saltwater, a pH neutral solution of hypochlorous acid, and its sodium salt, hypochlorite. The hypochlorous acid in Microcyn, similar to the natural hypochlorous acid produced by the human body, preserves the Microcyn solution.
“The unique solution chemistry imparted through the Microcyn manufacturing system provides superior product stability. Standard electrochemical processes used in the manufacture of other hypochlorous acid-containing products, cannot come close to matching this stability,” said Thornton.
“Microcyn solution aids in the mechanical removal of debris and foreign materials from the application site. Dirt debris and foreign material are mechanically removed by the action of the wound cleanser moving across the wound bed or application site with or without the assistance of a suitable wound dressing,” he adds.
“At 95 per cent water, Microcyn Skin and Wound Gel creates a moist wound environment that rehydrates necrotic tissue and promotes autolysis. These processes assist with the natural debridement process, thus enhancing the healing process,” informs Thornton.
“There are no known drug or treatment interactions or contraindications with Microcyn-based products. Testing has demonstrated the gel and liquid products to be non-irritating, non-sensitizing and non-toxic. Through additional testing, Microcyn-based liquid products have been found to have no oral toxicity, cause no ocular irritation and are non-genotoxic,” claimed Thornton.